ImmunityBio, Inc.
IBRXNASDAQHealthcare● Active
$7.13
+$0.21(+2.96%)
Market Cap$7.5B
P/E Ratio—
52W High$12.43
52W Low$1.95
ImmunityBio, Inc. (IBRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IBRX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.11B | $0.01B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.11B | $0.01B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | 99.34% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.21B | $0.19B | $0.23B | $0.25B | $0.20B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.37B | $0.36B | $0.36B | $0.35B | $0.33B |
| Operating Income | ($0.26B) | ($0.34B) | ($0.36B) | ($0.35B) | ($0.33B) |
| Operating Margin %(computed) | -226.00% | — | — | — | — |
| Interest Income | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.11B | $0.13B | $0.09B | $0.05B | $0.01B |
| Income Before Tax | ($0.35B) | ($0.41B) | ($0.58B) | ($0.42B) | ($0.35B) |
| Income Tax Expense | ($0.00B) | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Net Income | ($0.35B) | ($0.41B) | ($0.58B) | ($0.42B) | ($0.35B) |
| Net Margin %(computed) | -310.18% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.38 | $-0.59 | $-1.15 | $-1.04 | $-0.89 |
| Wtd Avg Shares | 0.92B | 0.70B | 0.51B | 0.40B | 0.39B |
| EBITDA | ($0.22B) | ($0.26B) | ($0.48B) | ($0.35B) | ($0.32B) |
| EBITDA Margin %(computed) | -197.34% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more ImmunityBio, Inc. data
About ImmunityBio, Inc. (IBRX) Income Statement
ImmunityBio, Inc. (IBRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IBRX reported revenue of $0.11B, gross profit of $0.11B (gross margin 99.34%), and net income of ($0.35B) — a net profit margin of -310.18%.
Frequently asked questions
IBRX · 4 questionsImmunityBio, Inc. (IBRX) reported revenue of $0.11B for 2025, up 668.3% year-over-year.
IBRX revenueIBRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08